All In Biotech

Drug Trial Radar · NCT03776968

A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics

A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics in Healthy Chinese Adults

Last checked: Nov 20, 2026Latest source record: Oct 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

47

Actual

Start

Oct 24, 2017

Primary completion

Jan 15, 2018

Study completion Jul 3, 2018

Sponsor

Lead sponsor
Hinova Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Dec 17, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase I study evaluating HC-1119 single-dose pharmacokinetics and effect of food on its pharmacokinetics in healthy Chinese adults. The study primary objective is to evaluate the HC-1119 pharmacokinetic characteristics and the effect of food on its pharmacokinetics in healthy Chinese males, subsequent to a single oral administration of HC-1119 with different doses in healthy Chinese males.

Conditions

  • Metastatic Castration Resistant Prostate Cancer

Interventions

  • HC1119Drug

    oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the plasma concentration-time curve from time 0 to infinity (∞) (AUC0-∞)Time frame: From the first dose of the study drug to day 50
  2. Area under the plasma concentration-time curve from time 0 to time t of the last measurable concentration(AUC0-t)Time frame: From the first dose of the study drug to day 50
  3. Peak concentration (Cmax)Time frame: From the first dose of the study drug to day 50
  4. Peak time (Tmax)Time frame: From the first dose of the study drug to day 50
  5. Elimination half life (t1/2)Time frame: From the first dose of the study drug to day 50
  6. Apparent clearance (CL/F) (prototype)Time frame: From the first dose of the study drug to day 50
  7. Apparent volume of distribution (Vd/F) (prototype)Time frame: From the first dose of the study drug to day 50
  8. Mean residence time (MRT)Time frame: From the first dose of the study drug to day 50

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Changhai Hospital Ethics Committee

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.